Evidence map›Paper›PMID 41737561›Full record

ArticleFrontiers in pharmacology2026

Unraveling the role of 3-mercaptopyruvate sulfurtransferase-derived hydrogen sulfide in triple-negative breast cancer chemoresistance.

Sousanna Hakim, Danira A Habashy, Kelly Ascenção, Rana A Youness, Carole Bourquin, Csaba Szabo, Mohamed Z Gad, Reham M Abdelkader

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sousanna HakimDepartment of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt.
Danira A HabashyDepartment of Clinical Pharmacy, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt.
Kelly AscençãoPharmacology Unit, Department of Oncology, Microbiology and Immunology, Section of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
Rana A YounessDepartment of Molecular Biology and Biochemistry, Faculty of Biotechnology, German International University, Cairo, Egypt.
Carole BourquinDepartment of Anesthesiology, School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, Pharmacology, Intensive Care and Emergency Medicine, University of Geneva, Geneva, Switzerland.
Csaba SzaboPharmacology Unit, Department of Oncology, Microbiology and Immunology, Section of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
Mohamed Z GadDepartment of Biochemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt.
Reham M AbdelkaderDepartment of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Triple-negative breast cancer (TNBC) frequently develops resistance to chemotherapy. Cancer-supporting roles of the endogenous gaseous mediator hydrogen sulfide (H Methods: A 3-MST inhibitor (HMPSNE) was used along with different chemotherapeutic drugs to determine whether 3-MST affects TNBC cell (MDA-MB-231) chemoresistance. H Results: HMPSNE enhanced the cytotoxic, anticlonogenic and antimigratory effects of doxorubicin on MDA-MB-231 cells. Doxorubicin increased H Conclusion: These findings suggest that TNBC chemoresistance is linked to the 3-MST/H2S pathway. Pharmacological inhibition of 3-MST by HMPSNE enhances the chemotherapeutic effect of doxorubicin on TNBC. Some of these effects may be related to the regulation of CD44 but are unlikely to be mediated via the PI3K/AKT/mTOR pathway. Therefore, pharmacological inhibition of 3-MST may serve as a promising target for further investigations to increase the sensitivity of TNBC cells to doxorubicin-based therapies.

Indexed as

3-MSTchemoresistancedoxorubicinH2STNBC

Identifiers

PMID41737561
PMCPMC12926708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.